Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use.
<h4>Objective and design</h4>The soluble urokinase plasminogen activator receptor (suPAR) has been recently recognized as a potential biological marker of various disease states, but the impact of a major surgical intervention on the suPAR level has not yet been established. The aim of o...
Guardado en:
Autores principales: | Waldemar Gozdzik, Barbara Adamik, Anna Gozdzik, Maciej Rachwalik, Wojciech Kustrzycki, Andrzej Kübler |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dcdc308be3ac4f7eac6661b36689fd9e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cardiac compression of lung lower lobes after coronary artery bypass graft with cardiopulmonary bypass.
por: Flávio H Neves, et al.
Publicado: (2013) -
Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants.
por: Eva Haastrup, et al.
Publicado: (2014) -
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
por: Line Jee Hartmann Rasmussen, et al.
Publicado: (2021) -
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19
por: Helena Enocsson, et al.
Publicado: (2021) -
Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor
por: Joseph Dowsett, et al.
Publicado: (2021)